Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
Myriad Genetics operating margin
Operating margin is operating income as a percentage of revenue.
Myriad Genetics's operating margin for the twelve months ending Jun 30, 2026 was -12.2%. For fiscal 2025 it was -47.0%, against -14.7% the year before. The highest annual figure on record is 39.2% in fiscal 2011.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -47.0% | −32.2 |
| FY2024 | Dec 31, 2024 | -14.7% | +19.4 |
| FY2023 | Dec 31, 2023 | -34.2% | −13.4 |
| FY2022 | Dec 31, 2022 | -20.7% | +15.6 |
| FY2020 | Jun 30, 2020 | -36.3% | −37.2 |
| FY2019 | Jun 30, 2019 | 0.9% | −15.5 |
| FY2018 | Jun 30, 2018 | 16.4% | +10.4 |
| FY2017 | Jun 30, 2017 | 6.0% | −14.7 |
| FY2016 | Jun 30, 2016 | 20.7% | +2.2 |
| FY2015 | Jun 30, 2015 | 18.5% | −16.8 |
| FY2014 | Jun 30, 2014 | 35.3% | −1.9 |
| FY2013 | Jun 30, 2013 | 37.2% | +0.8 |
| FY2012 | Jun 30, 2012 | 36.4% | −2.9 |
| FY2011 | Jun 30, 2011 | 39.2% | +2.0 |
| FY2010 | Jun 30, 2010 | 37.2% | −1.5 |
| FY2009 | Jun 30, 2009 | 38.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -20.4% | +134.1 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -15.3% | −0.5 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -2.7% | +15.8 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -11.3% | −2.0 |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -154.5% | −137.2 |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -14.8% | −1.0 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -18.5% | −2.5 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -9.4% | +21.9 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -17.3% | +44.7 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -13.8% | +15.0 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -16.0% | +13.4 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -31.3% | −2.5 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -62.0% | −52.0 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -28.8% | −13.3 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -29.4% | +43.9 |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -28.8% | +52.8 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -9.9% | −5.4 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -15.5% | −4.3 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -73.3% | −70.7 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -81.5% | −84.2 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -4.5% | −7.3 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -11.2% | −11.8 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -2.6% | −11.8 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | 2.7% | −4.8 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | 2.8% | −0.5 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | 0.6% | −46.4 |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | 9.2% | −0.3 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | 7.5% | +4.7 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | 3.4% | −5.4 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | 47.0% | +43.0 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | 9.5% | −3.4 |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | 2.8% | −19.5 |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | 8.7% | −14.6 |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | 4.0% | −19.6 |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | 12.8% | −6.0 |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | 22.4% | +2.5 |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | 23.4% | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | 23.6% | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | 18.8% | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | 19.8% | – |
See a number that looks wrong?